Protracted cocaine withdrawal produces circadian rhythmic alterations of phosphorylated GSK-3β in reward-related brain areas in rats

Behavioural Brain Research

Volumn 218, Issue 1, 2011, Pages 228-233

  Wei, Yi ming ^a   Li, Su xia ^b   Shi, Hai shui ^b   Ding, Zeng bo ^b   Luo, Yi xiao ^b   Xue, Yan xue ^b   Lu, Lin ^b   Yu, Chang xi ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Circadian rhythm; Cocaine; GSK 3 ; Protracted withdrawal

Indexed keywords

COCAINE; GLYCOGEN SYNTHASE KINASE 3BETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CIRCADIAN RHYTHM; CONTROLLED STUDY; FOOD PREFERENCE; MALE; MAZE TEST; NONHUMAN; NUCLEUS ACCUMBENS; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REWARD; SUPRACHIASMATIC NUCLEUS; VENTRAL TEGMENTUM; WEIGHT GAIN;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CIRCADIAN RHYTHM; COCAINE; GLYCOGEN SYNTHASE KINASE 3; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REWARD; SUBSTANCE WITHDRAWAL SYNDROME; SUPRACHIASMATIC NUCLEUS; VENTRAL TEGMENTAL AREA;

EID: 78650585934     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.054     Document Type: Article

References (69)

1. Wiessing L, Olszewski D, Klempova D, Vicente J, Griffiths P. EMCDDA annual report 2009: cocaine and heroin maintain firm hold on Europe's drug scene. Euro Surveill 2009; 14:pii: 19410 []. http://www.eurosurveillance.org/ViewArticle.aspx%3FArticleId=19410.
2. Kampman K.M., Volpicelli J.R., Mulvaney F., Rukstalis M., Alterman A.I., Pettinati H., et al. Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict Behav 2002, 27:251-260.
3. Poling J., Kosten T.R., Sofuoglu M. Treatment outcome predictors for cocaine dependence. Am J Drug Alcohol Abuse 2007, 33:191-206.
4. Gawin F.H., Kleber H.D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry 1986, 43:107-113.
5. Weddington W.W., Brown B.S., Haertzen C.A., Cone E.J., Dax E.M., Herning R.I., et al. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts: a controlled, residential study. Arch Gen Psychiatry 1990, 47:861-868.
6. Coffey S.F., Dansky B.S., Carrigan M.H., Brady K.T. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend 2000, 59:277-286.
7. Gillin J.C., Pulvirenti L., Withers N., Golshan S., Koob G. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report. Biol Psychiatry 1994, 35:843-849.
8. Kowatch R.A., Schnoll S.S., Knisely J.S., Green D., Elswick R.K. Electroencephalographic sleep and mood during cocaine withdrawal. J Addict Dis 1992, 11:21-45.
9. Satel S.L., Price L.H., Palumbo J.M., McDougle C.J., Krystal J.H., Gawin F., et al. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991, 148:1712-1716.
10. Flowers Q., Elder I.R., Voris J., Sebastian P.S., Blevins O., Dubois J. Daily cocaine craving in a 3-week inpatient treatment program. J Clin Psychol 1993, 49:292-297.
11. Martin S.D., Yeragani V.K., Lodhi R., Galloway M.P. Clinical ratings and plasma HVA during cocaine abstinence. Biol Psychiatry 1989, 26:356-362.
12. 123I]β-CIT SPECT. Am J Psychiatry 1998, 155:832-834.
13. Walsh S.L., Stoops W.W., Moody D.E., Lin S.N., Bigelow G.E. Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics. Exp Clin Psychopharmacol 2009, 17:205-216.
14. Beaulieu J.M. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 2007, 10:3-6.
15. Hooper C., Markevich V., Plattner F., Killick R., Schofield E., Engel T., et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 2007, 25:81-86.
16. Koros E., Dorner-Ciossek C. The role of glycogen synthase kinase-3β in schizophrenia. Drug News Perspect 2007, 20:437-445.
17. Mazanetz M.P., Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007, 6:464-479.
18. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7:1421-1434.
19. Martinek S., Inonog S., Manoukian A.S., Young M.W. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 2001, 105:769-779.
20. Hirota T., Lewis W.G., Liu A.C., Lee J.W., Schultz P.G., Kay S.A. A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3β Proc Natl Acad Sci USA 2008, 105:20746-20751.
21. Iitaka C., Miyazaki K., Akaike T., Ishida N. A role for glycogen synthase kinase-3β in the mammalian circadian clock. J Biol Chem 2005, 280:29397-29402.
22. Harada Y., Sakai M., Kurabayashi N., Hirota T., Fukada Y. Ser-557-phosphorylated mCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3β. J Biol Chem 2005, 280:31714-31721.
23. Yin L., Wang J., Klein P.S., Lazar M.A. Nuclear receptor Rev-erbα is a critical lithium-sensitive component of the circadian clock. Science 2006, 311:1002-1005.
24. Sahar S., Zocchi L., Kinoshita C., Borrelli E., Sassone-Corsi P. Regulation of BMAL1 protein stability and circadian function by GSK3β-mediated phosphorylation. PLoS One 2010, 5:e8561.
25. Xu C.M., Wang J., Wu P., Zhu W.L., Li Q.Q., Xue Y.X., et al. Glycogen synthase kinase 3β in the nucleus accumbens core mediates cocaine-induced behavioral sensitization. J Neurochem 2009, 111:1357-1368.
26. Miller J.S., Tallarida R.J., Unterwald E.M. Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 2009, 56:1116-1123.
27. Perrine S.A., Miller J.S., Unterwald E.M. Cocaine regulates protein kinase B and glycogen synthase kinase-3 activity in selective regions of rat brain. J Neurochem 2008, 107:570-577.
28. Giorgetti M., Zhdanova I.V. Chronic cocaine treatment induces dysregulation in the circadian pattern of rats' feeding behavior. Brain Res 2000, 877:170-175.
29. Abarca C., Albrecht U., Spanagel R. Cocaine sensitization and reward are under the influence of circadian genes and rhythm. Proc Natl Acad Sci USA 2002, 99:9026-9030.
30. Alsio J., Pickering C., Roman E., Hulting A.L., Lindblom J., Schioth H.B. Motivation for sucrose in sated rats is predicted by low anxiety-like behavior. Neurosci Lett 2009, 454:193-197.
31. Ashkenazy T., Einat H., Kronfeld-Schor N. Effects of bright light treatment on depression- and anxiety-like behaviors of diurnal rodents maintained on a short daylight schedule. Behav Brain Res 2009, 201:343-346.
32. + channel blocker riluzole show different neuroprotective profiles in reversing behavioral deficits induced by excitotoxic prefrontal cortex lesions. Neuroscience 2006, 137:211-220.
33. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
34. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
35. Lu L., Hope B.T., Dempsey J., Liu S.Y., Bossert J.M., Shaham Y. Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci 2005, 8:212-219.
36. Li Y.Q., Li F.Q., Wang X.Y., Wu P., Zhao M., Xu C.M., et al. Central amygdala extracellular signal-regulated kinase signaling pathway is critical to incubation of opiate craving. J Neurosci 2008, 28:13248-13257.
37. Mojon A., Fernandez J.R., Hermida R.C. Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol Int 1992, 9:403-412.
38. Baker S.L., Kentner A.C., Konkle A.T.M., Santa-Maria Barbagallo L., Bielajew C. Behavioral and physiological effects of chronic mild stress in female rats. Physiol Behav 2006, 87:314-322.
39. Liu A.C., Lewis W.G., Kay S.A. Mammalian circadian signaling networks and therapeutic targets. Nat Chem Biol 2007, 3:630-639.
40. Iijima M., Nikaido T., Akiyama M., Moriya T., Shibata S. Methamphetamine-induced, suprachiasmatic nucleus-independent circadian rhythms of activity and mPer gene expression in the striatum of the mouse. Eur J Neurosci 2002, 16:921-929.
41. Masubuchi S., Honma S., Abe H., Ishizaki K., Namihira M., Ikeda M., et al. Clock genes outside the suprachiasmatic nucleus involved in manifestation of locomotor activity rhythm in rats. Eur J Neurosci 2000, 12:4206-4214.
42. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Pychol Rev 1987, 94:469-492.
43. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 1988, 242:715-723.
44. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991, 14:299-302.
45. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993, 18:247-291.
46. Miller E.K. The prefrontal cortex and cognitive control. Nat Rev Neurosci 2000, 1:59-65.
47. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
48. Gurden H., Tassin J.P., Jay T.M. Integrity of the mesocortical dopaminergic system is necessary for complete expression of in vivo hippocampal-prefrontal cortex long-term potentiation. Neuroscience 1999, 94:1019-1027.
49. Baldwin A.E., Sadeghian K., Kelley A.E. Appetitive instrumental learning requires coincident activation of NMDA and dopamine D1 receptors within the medial prefrontal cortex. J Neurosci 2002, 22:1063-1071.
50. Jay T.M. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003, 69:375-390.
51. Kalivas P.W. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004, 4:23-29.
52. Kauer J.A., Malenka R.C. Synaptic plasticity and addiction. Nat Rev Neurosci 2007, 8:844-858.
53. Thomas M.J., Kalivas P.W., Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 2008, 154:327-342.
54. Chen B.T., Bowers M.S., Martin M., Hopf F.W., Guillory A.M., Carelli R.M., et al. Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA. Neuron 2008, 59:288-297.
55. Kourrich S., Rothwell P.E., Klug J.R., Thomas M.J. Cocaine experience controls bidirectional synaptic plasticity in the nucleus accumbens. J Neurosci 2007, 27:7921-7928.
56. Conrad K.L., Tseng K.Y., Uejima J.L., Reimers J.M., Heng L.J., Shaham Y., et al. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 2008, 454:118-121.
57. Sun X., Zhao Y., Wolf M.E. Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons. J Neurosci 2005, 25:7342-7351.
58. Dong Y., Nasif F.J., Tsui J.J., Ju W.Y., Cooper D.C., Hu X.T., et al. Cocaine-induced plasticity of intrinsic membrane properties in prefrontal cortex pyramidal neurons: adaptations in potassium currents. J Neurosci 2005, 25:936-940.
59. Kuhar M.J., Pilotte N.S. Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 1996, 17:260-264.
60. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28:166-172.
61. Beaulieu J.M., Sotnikova T.D., Gainetdinov R.R., Caron M.G. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem 2006, 281:32072-32080.
62. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004, 101:5099-5104.
63. Sotnikova T.D., Beaulieu J.M., Barak L.S., Wetsel W.C., Caron M.G., Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 2005, 3:e271.
64. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 2004, 36:131-137.
65. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
66. Zhu L.Q., Wang S.H., Liu D., Yin Y.Y., Tian Q., Wang X.C., et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 2007, 27:12211-12220.
67. Peineau S., Bradley C., Taghibiglou C., Doherty A., Bortolotto Z.A., Wang Y.T., et al. The role of GSK-3 in synaptic plasticity. Br J Pharmacol 2008, 153(Suppl 1):S428-S437.
68. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., et al. LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron 2007, 53:703-717.
69. Chen P., Gu Z., Liu W., Yan Z. Glycogen synthase kinase 3 regulates N-methyl-d-aspartate receptor channel trafficking and function in cortical neurons. Mol Pharmacol 2007, 72:40-51.